Customize your JAMA Network experience by selecting one or more topics from the list below.
Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
In Reply: The ER status of breast cancer was
determined based on clinical reports from the numerous sites that participated
in this international study; it was not feasible to mandate a single method.
Variability in the assessment of ER status might have led our study to underestimate
the differential effect of raloxifene on ER-positive and ER-negative cancer;
however, we found that these effects of raloxifene on risk of ER-positive
and ER-negative cancer were extremely different.
We disagree with Mr Kuo's assertion that the RR calculation should be
based only on participants who had ER-positive cancer. We believe that the
RR of ER-positive and ER-negative cancer was appropriately calculated by comparing
the rates of each type of cancer in the treatment group vs the placebo group.
Cummings SR, Grady D, Black D, et al. Estrogen-Receptor Status in Breast Cancer—Reply. JAMA. 2000;283(3):338–339. doi:10-1001/pubs.JAMA-ISSN-0098-7484-283-3-jac90010
Coronavirus Resource Center
Create a personal account or sign in to: